Top

Published in:

01-09-2011

Choosing a Treatment for Patients at the Time a Fracture is Presented

Author: S. Bobo Tanner

Published in: Current Osteoporosis Reports | Issue 3/2011

Abstract

The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.

Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2000;15:721–39.

Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39:203–9.PubMedCrossRef

Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16:953–62.PubMedCrossRef

Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473–7.PubMedCrossRef

Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404–15.PubMed

• Watts NB BJ, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of post menopausal osteoporosis. Endocr Pract. 2010;16 supplement 3:1–37. This is a comprehensive and useful set of guidleines for the management of osteoporosis.PubMed

Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431–7.PubMedCrossRef

•• Mehsen N, Paccou J, Confavreux CB, et al. Management of patients with incident fractures during osteoporosis treatment. Joint Bone Spine 2010;77 Suppl 2:S133–8. This article has a thoughtful series of six questions to use when evaluating the fracture patient already on osteoporosis treatment to help calrify if the patient is a “treatment failure” and how to procede.PubMedCrossRef

Nurmi-Lüthje I, Sund R, Juntunen M, Lüthje P. Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and anti-osteoporotic drugs are associated with lower mortality. A nationwide study in Finland. J Bone Miner Res. 2011;n/a–n/a.

10.

Gregory PC, Lam D, Howell P. Osteoporosis treatment following hip fracture: how rates vary by service. South Med J. 2010;103:977–81.PubMedCrossRef

11.

Owens GM. Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm. 2008;14:2–6.PubMed

12.

Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: New understandings based on three years’ experience with an osteoporosis care service. Arthritis Care Res. 2007;57:1502–6.CrossRef

13.

Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14:722–7.PubMedCrossRef

14.

• Semerano L, Guillot X, Rossini M, et al. What predicts initiation of osteoporosis treatment after fractures: education organisation or patients’ characteristics? Clin Exp Rheumatol 2011;29:89–92. This recent work speaks to the need for predischarge treatment initiation of osteoporosis treatment when a patient has been hospitalized with a fragility fracture. PubMed

15.

Kiebzak GM, Moore NL, Margolis S, et al. Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress. Am J Phys Med Rehabil. 2007;86:435–45.PubMedCrossRef

16.

Ellegaard M, Jørgensen N, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int. 2010;87:1–13.PubMedCrossRef

17.

• Bukata S, Puzas J. Orthopedic Uses of Teriparatide. Curr Osteoporos Rep. 2010;8:28–33. This is an excellent review of the details of teriparitide and its effects on fracture and bone healing.PubMedCrossRef

18.

Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res. 2007;22:1903–12.PubMedCrossRef

19.

Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2010;25:404–14.

20.

Chintamaneni S, Finzel K, Gruber B. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos Int. 2010;21:1059–63.PubMedCrossRef

21.

Barnes GL, Kakar S, Vora S, et al. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008;90:120–7.PubMedCrossRef

22.

Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, Vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96:1627–32.PubMedCrossRef

23.

Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol. 2010;29:1079–84.PubMedCrossRef

24.

Van Beek E, Lowik C, Que I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 1996;11:1492–7.

25.

Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677–92.PubMedCrossRef

26.

Roelofs AJ, Hulley PA, Meijer A, et al. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer. 2006;119:1254–61.PubMedCrossRef

27.

Adolphson P, Abbaszadegan H, Boden H, et al. Clodronate increases mineralization of callus after Colles’ fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71:195–200.PubMedCrossRef

28.

Van Der Poest Clement E, Patka P, Vandormael K, et al. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000;15:586–93.PubMedCrossRef

29.

Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.PubMedCrossRef

30.

Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77–85.PubMedCrossRef

31.

Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801–7.PubMedCrossRef

32.

•• Bukata SV. Systemic administration of pharmacological agents and bone repair: What can we expect. Injury 2011;In Press. This is the best summary of the current and future pharmacologic agents used with osteoporosis treatment and bone healing.

33.

McDonald MM, Dulai S, Godfrey C, et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43:653–62.PubMedCrossRef

34.

Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867–76.PubMedCrossRef

35.

Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg. 2009;34:595–602.CrossRef

36.

Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308–13.PubMedCrossRef

37.

Thillemann TM, Pedersen AB, Mehnert F, et al. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010;46:946–51.PubMedCrossRef

38.

Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2004;19:1779–86.

39.

Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med. 2010;362:1761–71.PubMedCrossRef

40.

Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728–37.PubMedCrossRef

41.

Milgrom C, Finestone A, Novack V, et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone. 2004;35:418–24.PubMedCrossRef

42.

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.PubMedCrossRef

43.

Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2010;25:2256–65.

44.

Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11:325–38.PubMedCrossRef

45.

Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24:196–208.PubMedCrossRef

46.

Adami S, Palacios S, Pavalka K, et al. FREEDOM TRIAL: densoumab is not associated with fracture healing complications in postmenopausal women with osteoporosis. Osteoporos Int. 2011;22 Suppl 1:S243–4.

Title: Choosing a Treatment for Patients at the Time a Fracture is Presented
Author: S. Bobo Tanner
Publication date: 01-09-2011
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 3/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-011-0061-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Choosing a Treatment for Patients at the Time a Fracture is Presented

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Minor, Major, Low-Trauma, and High-Trauma Fractures: What Are the Subsequent Fracture Risks and How Do They Vary?

Osteopenia: A Diagnostic and Therapeutic Challenge

The Role of Falls in Fracture Prediction

Osteoporosis: A Paradox in Ankylosing Spondylitis

The Role of Risk Communication in the Care of Osteoporosis

Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications